# Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

> **NCT03637556** · PHASE2 · COMPLETED · sponsor: **DisperSol Technologies, LLC** · enrollment: 25 (actual)

## Conditions studied

- Thalassemia Major

## Interventions

- **DRUG:** DST-0509
- **DRUG:** Jadenu
- **DRUG:** Exjade

## Key facts

- **NCT ID:** NCT03637556
- **Lead sponsor:** DisperSol Technologies, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-20
- **Primary completion:** 2021-06-08
- **Final completion:** 2021-08-16
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03637556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03637556, "Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03637556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*